Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.

Cancer letters - 1 Dec 2018

Kang Yeo Wool, Lee Ji Eun, Jung Kyung Hee, Son Mi Kwon, Shin Seung-Min, Kim Soo Jung, Fang Zhenghuan, Yan Hong Hua, Park Jung Hee, Han Boreum, Cheon Min Ji, Woo Min Gyu, Lim Joo Han, Kim Yong-Sung, Hong Soon-Sun

Abstract excerpt

Pancreatic cancer exhibits an oncogenic KRAS mutation rate of ∼90%. Despite research and drug development efforts focused on KRAS, no targeted therapy has been clinically approved for the treatment of pancreatic cancer with KRAS mutation. Also, the efficacy of gemcitabine is poor due to rapidly acquired resistance. We developed RT11-i antibody, which directly targets the intracellularly activated GTP-bound form...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Synergism

Share to Gemcitabine

Share to Mice, Nude

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 30217561
DOI: 10.1016/j.canlet.2018.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.PMID 30217561Read ↗

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersSemantic proximity Read ↗

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic CancerSemantic proximity Read ↗

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Semantic proximity Read ↗

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationSemantic proximity Read ↗

Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.